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SERIAL FECAL BIOMARKER MEASUREMENTS PREDICT RESPONSE TO 
BIOLOGIC THERAPY IN CHILDREN WITH IBD 
ERIKA MICHELLE MOXLEY 
ABSTRACT 
INTRODUCTION: The techniques currently in practice to diagnose and assess interval 
disease activity in patients with inflammatory bowel disease (IBD) are costly and 
invasive. Physicians typically rely on information derived from a combination of 
endoscopic, radiologic, and histologic studies to diagnose and determine the extent and 
severity of the two most common forms of IBD, Crohn disease (CD) and ulcerative 
colitis (UC). The development of noninvasive methods of assessing response to therapy 
is of increasing importance to pediatric healthcare providers. Previous studies have 
demonstrated that serum and fecal biomarkers are reliable measures of inflammation in 
the gastrointestinal tract. However, existing biomarkers are non-specific and their levels 
can be elevated in the context of either acute and chronic inflammation (IBD) or 
infection. As such, further studies are required to develop newer and novel biomarkers 
that have greater specificity for use in the diagnosis and interval assessment in children 
and adults with IBD. 
OBJECTIVES: The goal of this study is to further assess the relationship between 
biomarkers in the stool and serum of patients with IBD that are being treated with the 
anti-TNF therapy, infliximab (Remicade). To accomplish this, we will assess the changes 
in serum and fecal biomarker levels over the course of treatment and correlate the 
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changes in fecal and serum biomarker levels with clinical, biochemical, and endoscopic 
outcome variables. 
METHODS: We conducted a prospective longitudinal cohort study in pediatric patients 
with IBD receiving long-term immunosuppressive therapy with Remicade. Pediatric 
patients diagnosed with either CD or UC who receive Remicade at Boston Children’s 
Hospital were recruited. Patients were drawn from subsets of patients that were either 
naïve to Remicade, had received Remicade for less than 6 months, or had received 
Remicade for more than one year at the time of enrollment. We collected longitudinal 
data over the course of their first 6 consecutive infusions following enrollment, including 
blood and stool samples, disease activity indexes, as well as a patient-reported outcome 
measure (IMPACT-III Questionnaire) at each infusion session. 
RESULTS: A total of 33 patients with IBD who fit our eligibility criteria and provided 
informed consent were enrolled to date. Of these, 20 had a CD diagnosis and 13 had a 
UC diagnosis. We collected baseline serum, fecal, and IMPACT-III score data and 
followed enrolled patients over the course of subsequent infusions. Mean baseline fecal 
ASCA levels from 8 CD and 6 UC patients were  0.08±0.021 OD and 0.02±0.0015 OD, 
respectively. At baseline, serum lactoferrin (p<0.10), calprotectin (p<0.10), ESR 
(p<0.05), and CRP (p<0.10) were significantly higher among CD patients. 
CONCLUSION: Our data demonstrate the potential for serum and fecal biomarkers to 
evaluate therapeutic response to Remicade. Completion of study enrollment and data 
collection will be necessary to determine if individual or combinations of fecal and serum 
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biomarkers yield the most robust measures for use in the diagnosis and interval 
assessment of children and adults with IBD.  
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INTRODUCTION 
 
Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a family of idiopathic autoimmune diseases 
resulting in chronic inflammation of the gastrointestinal tract. IBD can be classified into 
two main forms, Crohn disease (CD) and ulcerative colitis (UC) (Zhang, 2014). Though 
closely related, CD and UC are heterogenous disease processes that differ in location, 
behavior, and molecular pathophysiology. In addition, these conditions can differ in   
clinical severity, the extent of inflammation, and the occurrence of extraintestinal 
manifestations (Panes, Jairath, & Levesque, 2017; Zhang, 2014). Patients can also be 
classified as having indeterminate colitis (IC) if the clinical features of their condition 
overlap with both CD and UC. Indeterminate colitis is more commonly diagnosed in 
children than in adults, as it is common for clinical features of IBD to evolve over time 
(Kelsen & Sullivan, 2017).  
While the exact pathogenesis of IBD is unknown, is likely to involve an 
interaction between genetic susceptibility, environmental factors, and intestinal bacterial 
flora, resulting in a dysregulated immune response within the intestinal mucosa. Common 
variants in over 160 genes have been identified that impart risk for IBD, 30 specific to 
CD and 23 specific to UC. As such, 110 genes overlap between the two forms, suggesting 
a genetic underpinning for an indeterminate phenotype (Zhang, 2014). However, genetic 
susceptibility alone is inadequate in explaining the cause of IBD. The incidence and 
prevalence of IBD are higher in Western societies and in developing countries, 
suggesting that environment also plays a substantial role in the pathogenesis of IBD (Ye, 
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Pang, Chen, Ju, & Zhou, 2015). One common explanation for this phenomenon is 
detailed in the “hygiene hypothesis”. The basis for this pathogenic mechanism is the 
observation that there has been a decrease in overall frequency of GI infection in Western 
societies over the course of the last four decades, and that this trend has negatively 
correlated with an increased frequency of autoimmune and allergic diseases (Bach, 
2017). This hypothesis suggests that factors such as early exposure to antibiotics, the 
popularization of cesarean sections, lack of exposure to breast milk, and increased dietary 
fat intake in developed countries are implicated risk factors for the development of IBD 
(Rosen, Dhawan, & Saeed, 2015). In addition, both active and passive exposure to 
smoking (especially in early life) results in a two-fold increase in the risk for CD. In 
terms of CD exacerbation, smoking is associated with an earlier age of onset, increased 
need for immunosuppressive therapy, higher overall disease severity, and increased need 
for surgical intervention. Conversely, smoking appears to be a protective factor for UC. 
While the mechanism(s) remain unclear, data demonstrate that tobacco smokers with UC 
have a reduction in overall disease severity, use of immunosuppression, and need for 
surgery (Malik, 2015).  
The commensal microbiome of the gastrointestinal (GI) tract is beneficial to the 
healthy host in terms of maintaining homeostasis, supporting GI development, and 
enhancing metabolic systems. Any dysregulation in the microbial community can have an 
adverse effect on host health. While a reduction in overall biodiversity of the intestinal 
mucosa has been observed in patients with active CD and UC (Ott, 2004), it remains 
unknown if this change contributes to the disease or if it is a byproduct of the 
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inflammation milieu (Abraham & Cho, 2009). In general, intestinal epithelial cells are 
responsible for acting as a physical barrier between the contents of the intestinal lumen 
and lymphoid tissue associated with the GI tract. Specialized epithelial cells, including 
mucus-producing goblet cells, and antimicrobial peptide releasing Paneth cells help to aid 
in the defense against bacterial invasion. Healthy mucosal barriers employ intercellular 
tight junctions to seal the paracellular space between adjacent epithelial cells and prevent 
bacteria and antigens from entering circulation. However, in the context of active 
inflammation, the paracellular space becomes increasingly permeable. This results in 
increased exposure of the immunocompetent cells found in the lamina propria to 
intestinal microbiota, further driving a mucosal inflammatory response. In healthy 
mucosa, damage resulting from GI inflammation is tightly regulated and ultimately 
resolved by conserved programs of epithelial regeneration and repair. In patients with 
IBD however, the inflammatory response often is self-sustained, resulting in ongoing 
injury to the epithelium, mucosal erosions and ulcerations, and a decrease in production 
of homeostatic antimicrobial peptides (Figure 1) (Abraham & Cho, 2009). 
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Figure 1: Factors mediating epithelial dysfunction in IBD (Coskun, 2014).  
 
Inflammatory bowel disease affects more than 1.5 million Americans (Malik, 
2015), with over 25% of patients with IBD presenting before 20 years of age (Rosen et 
al., 2015). Children and adolescents make up approximately 30% of the total IBD 
population and the incidence is increasing worldwide (Ye et al., 2015). CD is the most 
prominent subtype of pediatric IBD patients, comprising 59-73% of the patient 
population. Patients with UC make up 24-32% of the IBD population and the remaining 
are patients with IC. Epidemiologic data suggest that the age of onset of IBD impact 
clinical presentation, disease course, and disease extent (Yu & Rodriguez, 2017). 
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Clinical Features of IBD  
Patients with IBD present with a variety of gastrointestinal and extra-intestinal 
symptoms. In both CD and UC, abdominal pain and bloody diarrhea are common and 
early indicators of disease activity. While similar in some aspects, CD and UC are 
distinguishable by location, histological findings, and endoscopic evaluations. Ulcerative 
colitis affects only the intestinal mucosa, typically starting in the rectum and progressing 
proximally in a contiguous distribution. The gross appearance of the mucosa of patients 
with active UC is characterized by diffuse and continuous erythema, friability, 
granularity, and the loss of the underlying vascular pattern (Oliveira & Monteiro, 2017). 
Disease extent can be described using the Paris Classification. Inflammation limited to 
the rectum is termed ulcerative proctitis. Inflammation extending from the rectum to the 
splenic flexure is considered left-sided UC, while inflammation that extends beyond the 
splenic flexure is termed pancolitis (Eszter Müller, Laszlo Lakatos, Papp, & Veres, 
2014). 
Crohn disease is characterized by inflammation that can occur in all areas of the 
GI tract, with the potential to extend from mouth to anus. While UC only affects the 
mucosal layer of the intestine, the inflammation observed in patients with CD can involve 
all layers of the GI tract, from the mucosa into the serosa. The pattern and behavior of 
inflammation in patients with CD differ from UC as well, with endoscopic findings 
including a discontinuous disease distribution with deep fissuring ulcers, strictures, 
fistulas, and perianal disease (Figure 2). The Paris Classification defines CD by age at 
diagnosis, the location of inflammation, and the inflammatory behavior in terms of 
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stricturing and penetrating disease. Clinically, CD can evolve in phenotype over time 
with the potential to progress from inflammatory disease to stricturing or penetrating 
disease (Eszter Müller et al., 2014).  
 
Figure 2. Healthy versus IBD colon. These images are taken from endoscopic 
examinations of the large intestine. (a) Normal Colon. Smooth surface; no ulcerations, 
mucus, or pus. Normal vascular pattern. (b) UC Colon. Diffusely erythematous, 
granularity, limited circumference of the colon. (c) CD Colon. Thickened and nodular, 
deep ulcerations, discontinuous (Rufo & Bousvaros, 2006). 
 
Despite genotypic and phenotypic differences between subtypes, clinical 
manifestations are similar for most IBD patients and include abdominal pain, diarrhea, 
weight loss, anorexia, and rectal bleeding (Tang et al., 2017). However, the symptoms 
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experienced by a particular patient will vary based on disease location and behavior. 
Small intestinal involvement in pediatric patients with CD may present as growth delay, 
weight loss, and malnutrition. In contrast, patients with active Crohn disease of the large 
intestine may present similarly to that of UC as diarrhea, rectal bleeding, and abdominal 
pain. Consequences and complications of unrecognized or under-treated CD can result in 
growth failure and/or pubertal delay (Kelsen & Sullivan, 2017).  
Because IBD is a systemic disease, extraintestinal manifestations can affect 
multiple organ systems and are present in up to 28% of pediatric IBD patients at the time 
of diagnosis (Yu & Rodriguez, 2017). The biliary tract, eyes, joints, and skin are most 
commonly involved and manifest as pancreatitis, uveitis, peripheral arthritis, and 
psoriasis, among others (Vavricka et al., 2015). Extraintestinal manifestations are more 
commonly seen in patients with CD (Greuter et al., 2017). 
 
Diagnosis 
 The diagnosis of IBD and further discrimination between CD and UC require 
baseline lab testing, serological marker measurement, and endoscopic studies. Baseline 
lab tests typically include a complete blood count, liver enzymes, albumin, C reactive 
protein (CRP), and/or erythrocyte sedimentation rate (ESR) (Oliveira & Monteiro, 2017). 
ESR and CRP are useful inflammatory markers when viewed in the context of other 
clinical data. However, these tests have low specificity and may be influenced by a 
variety of disease factors. ESR measures the rate at which red blood cells settle into the 
plasma over a certain period of time, with increased rates being associated with infection, 
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inflammation, or trauma. CRP is a protein produced by the liver in response to 
inflammatory cytokines (primarily IL-6). Its role is to recognize and eliminate foreign 
pathogens and may help to clear necrotic or apoptotic cells. The level of CRP is typically 
proportional to the intensity of the inflammatory response occurring within the body 
(Bray et al., 2016). Serum antibodies, such as perinuclear-staining antineutrophil 
cytoplasmic (pANCA) and anti-sacharomyces cerevisiae antibodies (ASCA), also have a 
role in predicting disease activity within the scope of IBD (Mitsuyama, 2016).  
 Endoscopic studies are currently the gold standard for assessing IBD 
classification. During colonoscopy and upper GI endoscopy, mucosal biopsies are 
obtained and studied for histology (Oliveira & Monteiro, 2017). Colonoscopy 
examination typically includes the examination of the colon and end of the small intestine 
(terminal ileum). Upper GI endoscopic examination includes examination of the 
esophagus, stomach, and duodenum. Gross and histopathologic findings are important in 
distinguishing between CD and UC and determining the extent and severity of the 
disease. Both are part of first-line investigations for all cases of suspected IBD. 
Radiologic imaging of the small and large bowel can be used to further assess location, 
severity, and complications of CD. CAT scan and MRI enterography can be used to 
identify fistulas, abscesses, and intestinal strictures that are not typically visible on 
endoscopic examination (Rosen et al., 2015).  
 The Pediatric Crohn Disease Activity Index (PCDAI) and the Pediatric Ulcerative 
Colitis Activity Index (PUCAI) are two noninvasive disease metrics that can be used to 
assess clinical disease activity in pediatric patients with CD and UC, respectively. Both 
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assessments are derived from a composite of clinical findings to produce a numerical 
score with cut-off values defining disease activity. In addition, scores can also be used to 
assess a response to therapy (Yu & Rodriguez, 2017). Both metrics can be used by 
physicians to determine the best type of therapeutic intervention for their patients based 
on disease activity (J. S. Hyams et al., 1991). 
 The PCDAI score is comprised of subjective patient historical information, along 
with objective physical findings, laboratory results, and growth data (J. S. Hyams et al., 
1991). The PCDAI includes a 1-week recall of abdominal pain severity, general patient 
well-being, number of stools per day, abdominal pain, perirectal disease, weight, and 
presence of extraintestinal manifestation (J. S. Hyams et al., 1991; Yu & Rodriguez, 
2017). Scores range from 0-70, with a score less than 10 indicating remission and a score 
greater than or equal to 40 indicating severe disease. In addition, a score decrease of 12.5 
points or higher indicates an improvement in disease activity (Kapoor, Bhatia, & Sibal, 
2016). 
 The PUCAI assesses UC disease severity along the following clinical dimensions: 
abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal stools, and 
activity level. PUCAI scores range from 0-85, with a score less than 10 indicating 
remission and a score of 65 or higher indicating severe disease activity. A score decrease 
of >20 indicates improvement in disease activity. Cut-off scores for the PUCAI have over 
90% sensitivity and specificity in representing remission, mild, moderate, and severe 
disease activity in pediatric UC patients (Turner et al., 2007; Yu & Rodriguez, 2017).  
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Inflammatory Biomarkers 
 Biomarkers are objective, quantifiable indicators that can be utilized to measure 
normal biological or pathogenic processes in lieu of a reliance on more invasive and 
expensive clinical assessments (Strimbu & Tavel, 2010). Longitudinal changes in 
biomarkers are of increasing use to physicians as they may reflect or presage pathogenic 
processes occurring in the body before the patient expresses clinically significant 
symptoms. In the context of IBD, inflammation with infiltration of the intestinal mucosa 
by neutrophils and macrophages causes the secretion of proteins that can be detected in 
the stool (Bressler, Panaccione, Fedorak, & Seidman, 2015). The measurement of these 
proteins (biomarkers) is specifically useful in detecting intestinal mucosal inflammation 
and pharmacologic response to therapy (Angriman et al., 2007).   
 Anti-Saccharomyces cerevisiae antibodies (ASCA) are antiglycan antibodies 
directed against constituents in the cell wall of the yeast Saccharomyces cerevisiae 
(Mitsuyama, 2016). Prior studies have identified increased levels of ASCA in both the 
serum and stool of patients with IBD, lending to its potential application as a noninvasive 
marker of patients with IBD. ASCA has been found in 39-69% of patients with CD 
patients and in only 5-15% of patients with UC (Cioffi, 2015). Data from previous studies 
have demonstrated that fecal and serum ASCA levels are higher in patients with CD than 
in patients with UC (Tang et al., 2017). 
 Human lactoferrin is a 76kDa iron-binding glycoprotein produced by 
polymorphonuclear leukocytes, released by mucosal membranes during inflammatory 
processes, and can be measured in the serum and feces (Angriman et al., 2007). The 
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measurement of fecal lactoferrin is a sensitive and specific diagnostic tool for physicians 
to diagnose and assess disease activity in pediatric patients with active IBD, as levels of 
fecal lactoferrin have been shown to correlate with intestinal mucosal inflammation 
(Buderus, Boone, & Lentze, 2015).  
 Fecal calprotectin (FC) is a regulatory protein that functions in inflammatory, 
antimicrobial, and antiproliferative processes (Angriman et al., 2007). It is a 36.6-kDa 
non-glycosylated calcium and zinc-binding polypeptide, accounting for 60% of cytosolic 
proteins found in neutrophils and macrophages. Previous studies have determined FC to 
be a sensitive, though not disease specific, biomarker for use in assessing the presence of 
inflammation in the GI tract of children and adults. FC is increased in all pediatric GI 
diseases involving mucosal inflammation, including IBD, infectious enteritis, 
gastroesophageal reflux disease, and acute gastroenteritis. Specific to IBD, pediatric 
patients with active disease have been observed to have significantly higher levels of FC 
as compared to patients in remission (Berni Canani et al., 2004).  
 
Treatment 
 There is currently no cure for CD or UC. As such, the goal of IBD treatment is to 
reduce gut inflammation, improve clinical symptoms, and prevent complications of 
disease including the need for surgery, growth failure, pubertal delay, and poor social 
functioning. Traditional medical treatments for IBD include anti-inflammatory and 
immunosuppressive therapies, while new biological therapies have emerged that allow 
for more precise targeting of the immune system to maximize short- and long- term 
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benefits while minimizing risk (Baldwin & Kaplan, 2017). The choice of treatment for an 
individual patient, however, ultimately depends on disease classification (CD or UC), 
disease severity, location, phenotype, growth status, past clinical history, and response to 
previous therapy. In general, two decisions are considered when determining the course 
of treatment: which treatment to use for induction of remission, and which treatment to 
use for maintenance of remission (Oliveira & Monteiro, 2017).  
Corticosteroids were introduced in the 1950s and have since remained a mainstay 
in the treatment of patients with active IBD. They are effective in inducing remission in 
both CD and UC, though not typically used as maintenance therapy due to the serious 
side effects associated with their long-term use including weight gain, glucose 
intolerance, and bone demineralization. Corticosteroids are most often used in patients 
with moderate to severe disease. Although corticosteroids have displayed efficacy in 
most patients with active IBD, there remains a population of patients who are refractory 
to this therapy and thus require alternate treatment options. Aminosalicylates, such as 
mesalamine and sulfasalazine, are effective in inducing remission in 40-50% of pediatric 
patients with mild to moderate UC. While higher doses are used as induction therapy, 
lower doses can also be used to maintain remission. Thiopurines, a class of 
immunosuppressive agents including azathioprine and 6-mercaptopurine, have proven to 
be effective maintenance therapy for both CD and UC. However, due to typical delays in 
the onset of action (about 12 weeks), they are typically not useful for inducing remission 
in patients with active disease (Baldwin & Kaplan, 2017).  
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Biologic therapies, such as anti-tumor necrosis factor (TNF), have been developed 
as a byproduct of our increased understanding of the specific signaling pathways 
involved in the inflammatory response observed in patients with IBD. Anti-TNF agents 
have proved to be extremely effective treatments for patients with corticosteroid-
refractory IBD, and can be effective in both induction and maintenance therapy (Baldwin 
& Kaplan, 2017).  Infliximab (Remicade) has become an increasingly effective choice of 
therapy for pediatric IBD patients with chronically active disease who have lost response 
to first- and second-line therapies (Richmond et al., 2018). Infliximab is a chimeric 
monoclonal IgG antibody designed to bind specifically and neutralize tumor necrosis 
factor (TNF), a proinflammatory cytokine. It was originally approved for long term use 
of patients with moderate-to-severe CD, but has since also been used for treatment in UC 
and IC patients as well. Controlled data on the use of infliximab in pediatric patients with 
UC or IC is limited (Rufo & Bousvaros, 2006). In addition, while anti-TNF agents are 
currently among the most effective IBD therapies to date, it is possible for patients to 
develop anti-drug antibodies, thus rendering the drug ineffective and increasing the risk 
of allergic reactions over time (Baldwin & Kaplan, 2017). 
 
Health-Related Quality of Life Measurements  
 Health-related quality of life (HRQOL) has emerged as a standardized approach 
of determining the impact of disease burden on an individual, family unit, or population. 
Health-related quality of life measures patient perception of health status along with the 
effect of disease on physical, social, and emotional functioning. This subjective data can 
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be used individually or in combination with other more objective disease activity indices 
to determine how a disease affects the lives of patients and changes in response to 
therapy. In patients with chronic disease, HRQOL is especially important due to the 
potential for the lifelong impact of the illness on overall patient functioning (Abdovic et 
al., 2013).  
 The IMPACT-III Questionnaire was specifically developed to measure the quality 
of life of pediatric patients with IBD (J. Hyams et al., 2007). It is a self-report metric 
composed of 35 closed questions organized to evaluate patients along six domains: 
Bowel Symptoms (7 questions), Systemic Symptoms (3 questions), Social Functioning 
(12 questions), Body Image (3 questions), Treatment/Interventions (3 questions), and 
emotional functioning (7 questions). The IMPACT-III utilizes a five-point Likert scale, 
with scores ranging from 1 to 5 for each question. Overall scores range from 35 to 175, 
with higher scores indicating improved quality of life (Abdovic et al., 2013).   
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OBJECTIVES 
Data from previous studies have demonstrated the utility of measuring changes in 
fecal proteins for use in the diagnosis and interval assessment of patients with known or 
suspected inflammatory bowel disease. Data from this study will further assess the 
relationship between fecal and serum biomarkers, including ASCA, lactoferrin, 
calprotectin, and cytokine levels in pediatric patients with IBD on long term 
immunosuppressive therapy with Remicade (infliximab). The primary objective of this 
study is to assess absolute changes in fecal and serum biomarkers over time in pediatric 
patients with Crohn disease and ulcerative colitis. The secondary objective of this study is 
to assess the correlation between relative changes in biomarker levels and clinical, 
biochemical, and endoscopic outcome variables. We also analyze and compare 
longitudinal changes in GI symptoms and patient-reported quality of life.
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METHODS 
 
Study Design 
 We conducted a prospective longitudinal cohort study in pediatric patients with 
IBD patients receiving long term, intravenous immunosuppressive therapy with the 
biologic agent, infliximab (Remicade). This study was conducted at the Center for 
Ambulatory Therapy & Clinical Research (CAT/CR) at Boston Children’s Hospital, and 
in collaboration with Riley Children’s Hospital in Indianapolis. Patients with CD, UC, 
and IC, receiving infliximab infusions as maintenance therapy, were followed through six 
consecutive infusion appointments. 
 Eligibility criteria for this study included a diagnosis of  CD, UC, or IC, a plan to 
receive at least six consecutive infliximab infusions at Boston Children’s Hospital, and be 
21 years of age or younger. Exclusion criteria included: patients receiving infusions at 
other institutions (excluding Riley Children’s Hospital), patients that were withdrawn 
from consideration at the request of their primary GI provider, patients that were 
unwilling or unable to provide stool and serum samples, or a refusal to provide informed 
consent. This study was approved by the BCH institutional review board (IRB) under the 
protocol number IRB-P00023092. 
 
Study Participants 
 The goal of this study was to recruit a total of 50 patients at each of two study 
sites, distributed into categories by diagnosis and subcategories based on infliximab 
history. The three diagnostic categories included CD, UC, and IC. A patient’s Remicade 
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history was characterized by the time of their initial treatment and how many infusions 
they had received since that date. The three temporal subcategories included patients that 
were either in the midst of induction, post-induction for less than 6 months, and post-
induction for a year or more. Patients in the induction phase had received their first, 
second, or third infusions only. Patients in the post-induction <6 months phase had 
received over three infusions, but their first infusion was less than six months prior to 
their first sample collection. Lastly, patients in the post-induction >1 year had been 
receiving infliximab infusions for over one year and were past the induction phase. Each 
study site will recruit 30 patients with CD (10 induction, 10 post-induction <6 months, 10 
post-induction >1 year), 15 patients with UC (5 induction, 5 post-induction <6 months, 
and 5 post-induction >1 year), and 5 additional patients with IC from any temporal 
subcategory.  
 To date, a total of 33 patients have been enrolled in this study at the Boston 
Children’s Hospital site. The distribution of patients with CD includes 3 in the midst of 
induction, 7 post-induction for less than 6 months, and 10 that are post-induction for 
more than one year. The distribution of patients with UC includes 3 in the midst of 
induction, 5 patients that are post-induction for less than 6 months, and 5 patients that 
have been post-induction at least one year. We have not recruited to date any patients 
with IC. 
 
Participant Selection and Recruitment 
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 Patient eligibility was established using clinical data collected in PowerChart®, 
an electric medical record (EMR) database. If the patient met eligibility criteria based on 
past medical history, their primary GI provider was contacted to confirm eligibility and 
assess their propriety for participation in the study. Patients were then approached by 
Research Study Coordinators from the Inflammatory Bowel Disease Center during their 
scheduled infusion appointments in the CAT/CR of Boston Children’s Hospital. Research 
Study Coordinators introduced the study protocol, discussed the study requirements and 
procedures, and answered questions from patients and family members.  
After giving the family time to read the consent form, parental consent and patient 
assent (patient <18 years) were obtained. Once enrolled in the study, patients were assigned a 
distinct study ID number to ensure their privacy. 
 Patients were instructed to bring in one stool sample (about a tablespoon in 
volume) to each of their next six consecutive infliximab infusion appointments. Each 
participant was given six stool collection kits, each kit consisting of one of each of the 
following: stool hat, specimen cup, wooden specimen transfer apparatus, pair of latex 
gloves, medical facial mask, and a biohazard bag. Patients were provided with $35 for 
each stool sample brought in to offset their inconvenience and efforts. In addition, 5mL 
of blood was collected at each infusion in a venous blood collection tube (BD 
Vacutainer®). Lastly, patients filled out the Impact-III questionnaire, a self-report quality 
of life questionnaire for children with IBD, at each infusion.  
 
Sample Processing 
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After collection, blood and stool samples were brought to a research lab in the 
Enders building at Boston Children’s Hospital. Stool samples were divided into three 
2mL aliquots, individually labeled, batched and stored at -80ºC until ready for shipment 
to TECHLAB® Inc. (Blacksburg, Virginia) for processing. Blood samples were 
transferred into serum separator tubes and kept upright at room temperature for 30 min to 
allow for clotting. They were then spun in a centrifuge at 25ºC and 3000rpm for 10 
minutes. The serum was extracted using a pipette and divided into three 1mL aliquots in 
cryotubes. Serum samples were labeled, batched, and stored at -80ºC until ready for 
shipment to TECHLAB® Inc. 
 
Data Collection  
 Case report forms (CRF) for this study were created using the Research Electronic 
Data Capture (REDCap) platform, a secure web application used for assembling and 
managing data for research studies (Figures 3-9). The collection of patient data was 
facilitated by the use of electronic password protected CRF’s and extracted from 
PowerChart®. Protected health information (PHI) was excluded from the study data set 
to maintain patient privacy because our study involved sharing data with investigators 
outside of our home institution. The information collected in this study’s CRF were 
divided into nine domains: patient demographics, medications, disease location, Paris 
classification, infusion data, IMPACT-III questionnaire, special enrollment and testing, 
and subsequent colonoscopies. 
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Figure 3. CRF 1: Demographic data and Paris classification. 
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Figure 4. CRF 2: Paris classification (continued), medications, and disease location. 
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Figure 5. CRF 3: Infusion data. 
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Figure 6. CRF 4: Infusion data continued. 
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Figure 7. CRF 5: Infusion data (continued) and IMPACT-III questionnaire.  
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Figure 8. CRF 6: Enrollment and special testing and subsequent colonoscopies.  
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Figure 9. CRF 7: Subsequent colonoscopies continued.  
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RESULTS 
Patient Characteristics 
 A total of 33 patients (20 CD and 13 UC) have been enrolled in this study to date. 
The patient population is 58% male, with an average age of 14.8 years (SD 2.9). Further 
demographic data are presented in Table 1. Two hundred sixty patients were assessed for 
eligibility based on Remicade status. After initial screening, 61 patients were determined 
to be eligible based on IBD diagnosis, age, and GI provider approval, and 48 patients 
were approached to give informed consent. A flow chart of patient recruitment based on 
initial screening is presented in Figure 9. Recruitment results by category are presented 
in Table 2. 
 
Table 1. Demographic Data: Descriptive statistics of demographic values for a patient 
population of n=33. 
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Figure 10. Patient Recruitment: Flow chart of patient recruitment according to initial 
screening. 
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Table 2. Recruitment Results: This table depicts the breakdown of the patient populations 
recruited in this study. 
 
Baseline Biomarker Levels 
 Samples from 22 total patients were obtained and analyzed. Due to the 
longitudinal nature of this study, some patients were able to provide samples at multiple 
infusions while others were only able to provide baseline samples. At baseline, 16 serum 
samples were obtained from 8 CD and 8 UC patients, and 14 fecal samples were obtained 
from 8 CD and 6 UC patients. In addition, ESR and CRP inflammatory lab markers were 
measured in the blood samples of 13 CD patients and 9 UC patients. Serum ASCA and 
lactoferrin levels were measured from the serum samples. ASCA, lactoferrin, 
calprotectin, hemoglobin, IL1-α, and IL1-β were measured from collected fecal samples. 
Inflammatory lab markers included ESR and CRP. The data measured from these 
baseline samples are summarized in Table 3. IMPACT III surveys were also filled out by 
all patients and were included in the data analysis along with the biomarker data. 
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Table 3. Baseline Biomarker Data. This table depicts data measured from serum, fecal, 
and lab samples obtained from participants baseline infusion session. (a) CD Baseline 
Data. This table summarizes the data measured from CD patients at their baseline infusion. 
(b) UC Baseline Data. This table summarizes the data measured from UC patients at their 
baseline infusion. 
  
Measurements of Serum and Fecal ASCA Levels by Infusion  
 Data presented in Figure 11 reflect a comparison of serum ASCA levels in 
pediatric patients with CD and UC over the course of 5 consecutive infusions. We were 
unable to collect serum samples from patients at Infusion 4 at this time. The difference in 
serum ASCA levels was significant between CD and UC patients at Infusion 1 (p<0.10). 
A decrease in mean serum ASCA levels can be seen over time from Baseline to Infusion 
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5 among both the CD and UC populations. Serum ASCA is considered to be high with an 
optical density of over 0.080. Only one CD patient was identified with having high serum 
ASCA levels, with a level of 0.11 at Baseline and 0.117 at Infusion 1.  
The data presented in Figure 12 reflects a comparison of fecal ASCA levels 
between CD and UC patients over the course of 4 infusions. The difference in fecal 
ASCA levels in CD and UC patients was also significant between CD and UC patients at 
Infusion 1 (p<0.10). Mean fecal ASCA levels decreased from Baseline to Infusion 4 in 
the CD population, but remained stable at a value of 0.002 in the UC population. Fecal 
ASCA is considered to be high with an optical density of over 0.110. One CD patient was 
identified with having a high fecal ASCA level of 0.597 at Baseline. 
 
Figure 11. Serum ASCA Levels by Infusion: This figure compares the serum ASCA 
levels obtained from CD and UC patients from Baseline to Infusion 5. Serum ASCA 
levels are significant between the two populations at Infusion 1 (t=1.51, p=0.08).  
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Figure 12. Fecal ASCA Levels by Infusion: This figure compares the fecal ASCA levels 
obtained from CD and UC patients from Baseline to Infusion 3. Fecal lactoferrin levels are 
significant between the two populations at Infusion 1 (t=1.99, p=0.03).  
 
Measurement of Serum and Fecal Lactoferrin by Infusion 
 Data presented in Figure 13 reflects a comparison of serum lactoferrin levels 
between CD and UC patients starting from Baseline. We were unable to collect serum 
samples from patients at Infusion 4 at this time. The difference in serum lactoferrin levels 
was significant between CD and UC patients at Baseline (p<0.10), and among UC 
patients between Baseline and Infusion 1 (p<0.10). An overall decrease in mean serum 
lactoferrin levels can be seen over time from Baseline to Infusion 5 among both the CD 
population and UC population. The level of serum lactoferrin indicating inflammation is 
unknown.  
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The data presented in Figure 14 reflects a comparison of fecal lactoferrin levels 
between CD and UC patients over the course of 4 infusions. The difference in fecal 
lactoferrin levels between CD and UC patients was not significant at any infusion, and 
there were no significant changes in lactoferrin levels among the CD or UC populations 
from Baseline to Infusion 3. Fecal lactoferrin is considered to be high when >7.25 g/g. 
While fecal lactoferrin levels of 10-20 g/g indicate small levels of inflammation, fecal 
lactoferrin levels >100 g/g may indicate substantial inflammation. A total of 7 patients 
(6 CD and 1 UC) were identified with having high fecal lactoferrin levels at Baseline 
(CD: 30 g/g, 83 g/g, 17 g/g, 15 g/g, 97 g/g, 21 g/g; UC: 351 g/g). In addition, 3 
patients (2 CD and 1 UC) were identified with having high fecal lactoferrin at Infusion 1, 
and 2 were identified at Infusion 2 (1 CD and 1 UC). Of this group, 1 CD patient was 
identified to have sustained high fecal lactoferrin levels from Baseline to Infusion 1. 
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Figure 13. Serum Lactoferrin Levels by Infusion: This figure compares the serum 
lactoferrin levels obtained from CD and UC patients from Baseline to Infusion 5. Serum 
lactoferrin levels are significant between the two populations at Infusion 1 (t=1.56, p=0.07) 
and Infusion 2 (t=2.33, p=0.03), and for the UC population between Baseline and Infusion 
1 (t=-1.62, p=0.06).  
 
 
Figure 14. Fecal Lactoferrin Levels by Infusion: This figure compares the fecal 
lactoferrin levels obtained from CD and UC patients from Baseline to Infusion 3. 
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Measurement of Fecal Calprotectin Levels by Infusion 
 Data presented in Figure 15 reflects a comparison of fecal calprotectin levels 
from Baseline to Infusion 3 and between the CD and UC population at each infusion. 
Fecal calprotectin was unable to be measured at Baseline for one patient and at Infusion 1 
for one other patient due to insufficient quantity. The difference in fecal calprotectin 
levels between the CD and UC  population was significant at Baseline (p<0.10), and 
among the UC population between Baseline and Infusion 1 (p<0.10). Fecal calprotectin 
levels are considered borderline when measuring 50-120 g/g, and abnormally high when 
measuring >120 g/g. At baseline, 5 patients (5 CD) were identified with abnormally 
high levels of fecal calprotectin (144 g/g, 237 g/g, 174 g/g, 591 g/g, 245 g/g), and 
4 (1 CD and 3 UC) patients were identified with borderline levels (CD: 73 g/g; UC: 
52 g/g, 73 g/g, 108 g/g). At Infusion 1, 1 CD patient was identified as having a 
borderline elevation in fecal calprotectin (55 g/g) and 2 CD patients were identified with 
high fecal calprotectin (666 g/g, 168 g/g). Lastly, 2 patients (1 CD and 1 UC) were 
identified with having borderline elevations in fecal calprotectin levels at Infusion 2 (CD: 
95 g/g; UC: 53 g/g). Overall from this group, two patients with abnormally high levels 
at Baseline were measured at subsequent infusions, one of which was a CD patient who 
sustained borderline levels at Infusion 1 and Infusion 2. The other patient was a CD 
patient with over 250% increase in fecal calprotectin from Baseline to Infusion 1.  
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Figure 15. Fecal Calprotectin Levels by Infusion: This figure compares the fecal 
calprotectin levels obtained from CD and UC patients from Baseline to Infusion 3. Fecal 
calprotectin levels are significant between the two populations at Baseline (t=1.57, 
p=0.07), and for the UC population between Baseline and Infusion 1 (t=1.59, p=0.08). 
 
Measurement of Fecal Hemoglobin Levels by Infusion  
 Data presented in Figure 16 reflects a comparison of fecal hemoglobin levels 
from Baseline to Infusion 3 and between the CD and UC population at each infusion. 
Differences in fecal hemoglobin levels between the CD and UC populations were not 
significant at any infusion, nor were they significant among either population over time. 
Fecal hemoglobin is considered high when 15 g/g. Two patients (1 CD and 1 UC) 
were identified with high levels of fecal hemoglobin at baseline (CD: 18 g/g ; UC: 
405 g/g).   
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Figure 16. Fecal Hemoglobin Levels by Infusion: This figure presents the fecal 
hemoglobin levels obtained from CD and UC patients from Baseline to Infusion 3. 
 
Measurement of Fecal IL1-α Levels by Infusion 
Data presented in Figure 17 reflects a comparison of fecal IL1-α levels from 
Baseline to Infusion 3. Fecal IL1-α measures were unable to be collected from the stool 
sample of one patient due to insufficient quantity. The difference in fecal IL1-α levels 
was significant between CD and UC patients at Infusion 2 (p<0.05), and among UC 
patients between Baseline and Infusion 2 (p<0.05). Fecal IL1-α is considered high when 
>2051 pg/g. Two UC patients were identified with high fecal IL1-α at Infusion 2 (2933 
pg/g, 3124 pg/g).    
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Figure 17. Fecal IL1-α Levels by Infusion: This figure compares the fecal IL1-α levels 
obtained from CD and UC patients from Baseline to Infusion 3. Fecal IL1-α levels are 
significant between the two populations at Infusion 2 (t=2.84, p=0.02), and for the UC 
population between Baseline and Infusion 2 (t=-2.92, p=0.01). 
 
Measurement of Fecal IL1-ß Levels by Infusion 
Data presented in Figure 18 reflects a comparison of fecal IL1-ß levels from 
Baseline to Infusion 3 and between the CD and UC population at each infusion. Fecal 
IL1-ß levels recorded in patients with CD and UC were not significant at any infusion nor 
were they significant among either population over time. Fecal IL1-ß is considered high 
when >101 pg/g. At Baseline, 1 UC patient was identified with a level of 5937 pg/g. This 
patient had normal levels at Infusion 1 but sustained high levels at Infusion 2 (483 pg/g). 
Another UC patient had high levels of fecal IL1-ß at Infusion 2 (1009 pg/g).  
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Figure 18. Fecal IL1-ß Levels by Infusion: This figure compares the fecal IL1-ß levels 
obtained from CD and UC patients from Baseline to Infusion 3. 
 
Measurement of ESR by Infusion 
 Data presented in Figure 19 reflects the change in ESR levels from Baseline to 
Infusion 5 and between the CD and UC population at each infusion. The difference in 
ESR levels was significant between the CD and UC population at Baseline (p<0.05) and 
Infusion 1 (p<0.05). ESR is considered high when >35 mm/hr. Two CD patients had  
high ESR levels, one with a Baseline ESR of 38 mm/hr and one with an Infusion 3 ESR 
of 43 mm/hr. The patient with high Baseline ESR normalized at Infusion 1. 
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Figure 19. ESR Levels by Infusion: This figure compares ESR levels obtained from CD 
and UC patients from Baseline to Infusion 5. ESR levels are significant between the two 
populations at Baseline (t=2.03, p=0.03) and Infusion 1 (t=1.40, p=0.09). 
 
Measurement of CRP by Infusion 
 Data presented in Figure 20 reflects the change in CRP levels from Baseline to 
Infusion 5 between the CD and UC population at each infusion. The difference in CRP 
levels was significant between the CD and UC population at Baseline (p<0.10) and 
Infusion 1 (p<0.05). In addition, the CRP levels differed significantly among the UC 
population from Baseline to Infusion 3 (p<0.05) and from Baseline to Infusion 4 
(p<0.05). CRP is considered high when 0.5mg/dL. Three CD patients had high CRP at 
Baseline (0.86 mg/dL, 1.82 mg/dL, 0.66 mg/dL), one CD patient had high CRP at 
Infusion 1 (0.74 mg/dL), and one UC patient had high CRP at Infusion 4 (4.93 mg/dL).   
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Figure 20. CRP Levels by Infusion: This figure compares CRP levels obtained from CD 
and UC patients from Baseline to Infusion 5. CRP levels are significant between the two 
populations at Baseline (t=1.42, p=0.09) and Infusion 1 (t=1.86, p=0.04), and for UC 
patients between Baseline and Infusion 3 (t=-2.21, p=0.03), and Baseline and Infusion 5 
(t=2.70, p=0.01).  
 
Comparison of IMPACT III Scores between Populations 
 The IMPACT-III scores collected in this study ranged from 35 to 175, with higher 
scores suggesting better quality of life. The mean IMPACT-III scores at baseline was 
77.1±16.3 for CD patients and 69±15.2 for UC Patients (Table 4). The mean IMPACT-
III scores between the two groups was not statistically significant at Baseline (p=0.24). 
However, scores from the CD patient population were significantly increased from 
Baseline to Infusion 2 (p<0.10).  
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Table 4. IMPACT-III Data. This table depicts IMPACT-III Questionnaire scores taken 
at Baseline and each consecutive infusion. (a) CD IMPACT-III Scores. This table 
summarizes the IMPACT-III scores measured from CD patients from Baseline to Infusion 
4. (b) UC IMPACT-III Scores. This table summarizes the IMPACT-III scores measured 
from UC patients form Baseline to Infusion 5.  
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DISCUSSION 
 
Data from previous studies have demonstrated the utility of measuring changes in 
fecal proteins for use in the diagnosis and interval assessment of patients with known or 
suspected inflammatory bowel disease. The goal of this study was to continue this line of 
investigation to assess the relationship between levels of inflammatory biomarkers in 
serum and stool of patients with IBD on long term immunosuppressive therapy with 
Remicade (infliximab). Our primary objective was to assess absolute and changes in fecal 
and serum biomarker levels over time in pediatric patients with Crohn disease and 
ulcerative colitis. The secondary objective was to assess the correlation between changes 
in fecal biomarker levels and clinical, biochemical, endoscopic, and outcome variables. 
We analyzed and compared longitudinal changes in GI symptoms and perceived quality 
of life in patients receiving long term immunosuppressive therapy for management of 
their IBD.  
 We present the preliminary results here. We recognized that this is a longitudinal 
study and further data collection is necessary for a complete data analysis. With 
subsequent infusion data, we will be able to determine with greater certainty whether 
serum and fecal biomarker levels can be used to monitor disease state, as well as whether 
they can be used to differentiate between UC and CD patient populations.  
 We observed higher mean and median baseline serum and fecal ASCA levels in 
CD patients as compared to UC patients. These findings are consistent with data 
presented in other studies suggesting that both serum and fecal ASCA levels are higher in 
CD patients at baseline, relative to those measured in patients with UC and in healthy 
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controls. In addition, while mean serum ASCA levels decreased over subsequent 
infusions in patients with CD patients, serum ASCA in UC patients remained stable. One 
patient with CD with a high serum ASCA was admitted to Boston Children’s Hospital 
while enrolled in our study for medical management of flare in their Crohn disease 
manifesting as diarrhea, fatigue, and weight loss. This patient was refractory to oral 
steroids and transitioned from Remicade to vedolizumab for long term management. As 
such, this patient was dropped from our study after Infusion 1. This patient’s elevated 
serum ASCA levels were measured prior to admission. This aligns with data from prior 
studies suggesting that ASCA levels are higher for CD patients in active disease states, 
increasing the potential for serum ASCA to be a reliable biomarker of clinical disease 
activity. One CD patient identified with high fecal ASCA also had abnormally high levels 
of fecal lactoferrin, calprotectin, and hemoglobin at Baseline. However, 
contemporaneous ESR and CRP levels were normal. This patient did not have recent 
clinic notes suggesting active disease around the time that this level was measured. We 
were unable to collect a serum sample from this patient at the Baseline infusion, so we 
could not compare the fecal ASCA levels to this patient’s serum ASCA levels.  
 We observed higher mean serum lactoferrin in the CD population as compared to 
the UC population at baseline, but median serum lactoferrin levels were nearly the same. 
We observed higher baseline fecal lactoferrin in the UC population. In both the serum 
and fecal lactoferrin data sets, there was an overall decrease in mean lactoferrin over 
subsequent infusions in the CD population, while the mean levels were more stable in the 
UC population. Serum lactoferrin levels differed significantly among the CD and UC 
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population at Baseline and Infusion 2 but with opposite results: at Baseline, the serum 
lactoferrin levels from CD patients was significantly higher than the levels measured 
from UC patients, and at Infusion 2 the UC population had significantly higher levels 
than the CD population. The data trend suggests that Remicade may be more effective in 
sustaining a decreased level of inflammation in CD patients, at least early in the course of 
treatment. Fecal lactoferrin levels were not significant across either population at 
Baseline or when collected at subsequent infusions.  
 Fecal calprotectin levels were generally higher in the CD population, and there 
were significant differences in the levels of fecal calprotectin between the CD and UC 
populations at baseline. Overall, we observed a higher percentage of CD patients with 
abnormally high levels of fecal calprotectin and a higher percentage of UC patients with 
borderline levels of fecal calprotectin at baseline. Of all patients with elevated fecal 
lactoferrin, we observed a concurrent increase in fecal calprotectin levels in only the CD 
population. We could not identify this same pattern in the UC population, as the one UC 
patient with elevated fecal lactoferrin had an insufficient quantity to determine fecal 
calprotectin levels. However, the UC patients who had elevated fecal calprotectin levels 
had normal levels of fecal lactoferrin. This suggests that we may be able to use a ratio of 
fecal lactoferrin and calprotectin levels to differentiate between IBD diagnostic 
categories. However, serum calprotectin was not measured in this study.  
 Mean fecal hemoglobin levels were elevated at baseline in the UC population, 
though the median levels between the two populations were both 0 g/g. Fecal 
hemoglobin levels were normal in all but 2 patients during the interval between Baseline 
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and Infusion 3. One CD patient had slightly elevated fecal hemoglobin at baseline, which 
also coincided with an elevation in fecal ASCA, lactoferrin, and calprotectin. However, 
this patient was previously mentioned in the discussion and is not indicated to have active 
disease at this time. It is of importance to continue to follow this patient’s disease course 
throughout our study to determine if an increase in these inflammatory markers may 
precede active disease. A UC patient had extremely elevated fecal hemoglobin levels 
which coincided with an elevation in fecal lactoferrin as well. This patient’s fecal ASCA, 
ESR, and CRP were all normal. Fecal calprotectin levels could not be measured in this 
patient as a result of insufficient quantity. This patient had a history of bloody stool two 
weeks prior to this fecal sample measurement and was noted to be on prednisone, 
indicating active disease. At a clinic appointment approximately 3 months later, this 
patient’s physician noted a PUCAI score of 0, indicating clinical remission. 
 Mean and median fecal IL1-α levels were elevated in the UC population at 
Baseline. Fecal IL1-α levels differed significantly between the UC and CD population at 
Infusion 2, and among the UC population from Baseline to Infusion 2. Of the two UC 
patients with elevated levels at Infusion 2, one had concurrent elevated fecal calprotectin 
and lactoferrin levels while the other had otherwise normal levels. Mean fecal IL-ß levels 
were also elevated in the UC population at Baseline. There were not significant 
differences between populations at or between individual infusions. In general, however, 
mean IL1- ß levels in CD patients remained stable over from Baseline to Infusion 3, 
while they varied in the UC patient population.  
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 The inflammatory lab markers, ESR and CRP, were higher in the CD patient 
population at Baseline as compared to the UC patient population. With respect to both 
markers, the CD group had significantly higher levels at Baseline and Infusion 1. While 
ESR levels in either patient population did not differ significantly over time, we observed 
a significant increase in CRP levels in the UC patient population from Baseline to 
Infusion 3 and from Baseline to Infusion 4.  
 With respect to quality of life, we observed higher overall IMPACT-III scores at 
Baseline in the CD patient population as compared to the UC patient population. There 
was an overall increase of 16 points from Baseline to Infusion 4 in the CD patient 
population, and an overall increase of 13 points from Baseline to Infusion 4 in the UC 
patient population. The mean total score in the UC group at Infusion 5 was 115.  
However, this data was collected from only one subject and this is not likely not to be 
indicative of the overall group trend. This suggests that clinical improvements resulting 
from Remicade treatment may have a positive impact on a patient’s quality of life.  
 The overall goal of this study is to recruit 50 total patients and to follow each 
through 6 total infusions, starting from Baseline to Infusion 5. This enrollment 
specification was chosen in an effort to collect data from distinct patient populations in 
terms of treatment response. We have 17 remaining patients to recruit for this study, 
which includes 10 CD, 2 UC patients, and 5 IC patients. In addition, we will continue to 
collect data from current patients at subsequent infusions.  
 The present study is not without limitations. Because this study took place in an 
outpatient setting, it required patients to remember and bring in stool samples to their 
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infusion sessions. Although we were able to contact patients and their guardians to give 
reminders, there was no certainty that they would remember to bring the sample to the 
infusion center. Therefore, fecal data may be inconsistent at times among specific 
patients. Similar factors hold true in obtaining serum and IMPACT-III data. Because the 
patients enrolled in this study were drawn from a population of patients receiving 
ambulatory infusions, scheduling conflicts have and will continue to occur due to 
unforeseeable events. Although we do have access to the infusion center schedule, 
patients may reschedule, arrive early, or cancel without notice.   
  In summary, there existed several differences in biomarker levels, specifically 
inflammatory markers, to distinguish between a CD and UC diagnosis in patients with 
suspected IBD. It is our hope that throughout the remainder of this study, we will obtain 
more convincing data that will allow us to demarcate true trends in biomarker levels in 
order to assess disease activity in IBD patients.  
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CONCLUSION 
 
 Our findings further support the hypothesis that serum and fecal biomarkers can 
be used to diagnose and evaluate therapeutic response to Remicade in children and young 
adults with CD and UC. While prior studies on biomarkers have demonstrated the utility 
of measurements in determining the presence and extent of inflammation in the GI tract, 
they lack the specificity necessary to differentiate between disease form and activity. The 
preliminary data from this study suggest that there may be differences in biomarker levels 
between IBD groups, though further investigations are necessary to fully elucidate the 
specificity of the ASCA biomarker in relation to more heavily studied biomarkers such as 
lactoferrin and calprotectin. While this study has started to shed light on the utility of 
biomarkers in the context of IBD, the completion of this longitudinal study is necessary 
to obtain a full assessment of the efficacy of biomarkers in distinguishing disease form 
and assessing severity and extent. This study is also being performed in collaborations 
with investigators at the Riley Children’s Hospital in Indianapolis. Through ongoing and 
future collaborations, we hope to plan and execute larger studies with greater statistical 
power to generate findings that will better inform clinicians and researchers with 
additional epidemiologic and prognostic outcome data. 
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